Evidence map›Paper›PMID 25203674›Full record

ArticleMolecular endocrinology (Baltimore, Md.)2014

A natural androgen receptor antagonist induces cellular senescence in prostate cancer cells.

Wiebke Hessenkemper, Julia Roediger, Sophie Bartsch, Adriaan B Houtsmuller, Martin E van Royen, Iver Petersen, Marc-Oliver Grimm, Aria Baniahmad

Open access · bronzeAbstract read
In one paragraph

Article in Molecular endocrinology (Baltimore, Md.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 56 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Wiebke HessenkemperInstitute of Human Genetics (W.H., J.R., S.B., A.B.), Institute of Pathology (I.P.), and Institute of Urology (M.-O.G.), Jena University Hospital, 07740 Jena, Germany; Department of Pathology (A.B.H., M.E.v.R.), Josephine Nefkens Institute, and Erasmus Optical Imaging Center (A.B.H., M.E.v.R.), Erasmus Medical Center, 3000 CA Rotterdam, The Netherlands.
Julia Roediger
Sophie Bartsch
Adriaan B Houtsmuller
Martin E van Royen
Iver Petersen
Marc-Oliver Grimm
Aria Baniahmad
Jena University Hospital · DEImaging Center · USMeertens Institute · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We have previously identified a natural occurring, androgen receptor-specific antagonist. Atraric acid (AA) inhibits the transactivation of the androgen receptor (AR) and androgen-mediated growth of AR-expressing human prostate cancer (PCa) cell lines. Here we show that AA treatment of living cells provokes molecular changes of AR signaling. In addition to a deceleration of nuclear translocation a block of the intramolecular amino/carboxy (N/C)-terminal interaction of the AR was observed. Furthermore, using high-resolution confocal fluorescence microscopy, a reduced speckle formation of the AR was observed in line with an increased intranuclear mobility of the receptor. This suggests decreased DNA binding of the AR, which is further indicated by an impaired chromatin recruitment of the AR to the prostate-specific antigen promoter and enhancer shown by chromatin immunoprecipitation experiments. Using inhibitors of the non-receptor tyrosine kinase Src or Akt, known interaction partners of AR, reduced the level of androgen-induced cellular senescence suggesting a partly non-genomic pathway to induce cellular senescence by AA. Using PP2 (4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine) pyrimidine or Akt inhibitors, inhibitors of the nonreceptor tyrosine kinase Src or Akt, known interaction partners of AR, reduced the level of androgen-induced cellular senescence, suggesting a partly nongenomic pathway to induce cellular senescence by AA. Treatment of LNCaP cells with AA is associated with hypophosphorylation of the retinoblastoma tumor suppressor and an increase of p16 expression, whereas the p53-p21 signaling pathway seems not be affected by AA treatment. Analyzing human PCa tissue samples treated with AA ex vivo also indicates an induction of cellular senescence associated with an increase of p16 expression but not p21. Taken together, these data indicate that AA exhibits novel features to inhibit AR amino/carboxy-terminal interaction, the AR-mediated nuclear activities and growth of PCa cells.

Indexed as

Androgen Receptor AntagonistsAndrogensCell Line, TumorCellular SenescenceCyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p21Gene Expression Regulation, NeoplasticHumansMaleProstateProstate-Specific AntigenProstatic NeoplasmsProto-Oncogene Proteins c-aktReceptors, AndrogenSignal Transductionsrc-Family KinasesAndrogen Receptor AntagonistsAndrogensAR protein, humanCDKN1A protein, humanCyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p21Prostate-Specific AntigenProto-Oncogene Proteins c-aktReceptors, Androgensrc-Family KinasesTumor Suppressor Protein p53

Identifiers

PMID25203674
PMCPMC5414792
OpenAlexW2133021077

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.